REFERENCES
1. Prinz WA, Toulmay A, Balla T. The functional universe of membrane contact sites. Nat Rev Mol Cell Biol. 2020;21:7-24.
2. Sun S, Zhao G, Jia M, et al. Stay in touch with the endoplasmic reticulum. Sci China Life Sci. 2024;67:230-57.
3. Wenzel EM, Elfmark LA, Stenmark H, Raiborg C. ER as master regulator of membrane trafficking and organelle function. J Cell Biol. 2022:221.
4. Domingues N, Pires J, Milosevic I, Raimundo N. Role of lipids in interorganelle communication. Trends Cell Biol. 2025;35:46-58.
5. Parkkinen I, Their A, Asghar MY, Sree S, Jokitalo E, Airavaara M. Pharmacological regulation of endoplasmic reticulum structure and calcium dynamics: importance for neurodegenerative diseases. Pharmacol Rev. 2023;75:959-78.
6. Acosta-Alvear D, Harnoss JM, Walter P, Ashkenazi A. Homeostasis control in health and disease by the unfolded protein response. Nat Rev Mol Cell Biol. 2025;26:193-212.
7. Murphy SE, Levine TP. VAP, a Versatile access point for the endoplasmic reticulum: review and analysis of FFAT-like motifs in the VAPome. Biochim Biophys Acta. 2016;1861:952-61.
8. Neefjes J, Cabukusta B. What the VAP: The expanded VAP family of proteins interacting with FFAT and FFAT-related motifs for interorganellar contact. Contact (Thousand Oaks). 2021;4:25152564211012246.
9. James C, Kehlenbach RH. The interactome of the VAP family of proteins: An overview. Cells. 2021;10:1780.
10. Loewen CJ, Levine TP. A highly conserved binding site in vesicle-associated membrane protein-associated protein (VAP) for the FFAT motif of lipid-binding proteins. J Biol Chem. 2005;280:14097-104.
11. Di Mattia T, Wilhelm LP, Ikhlef S, et al. Identification of MOSPD2, a novel scaffold for endoplasmic reticulum membrane contact sites. EMBO Rep. 2018:19.
12. Cabukusta B, Berlin I, van Elsland DM, et al. Human VAPome analysis reveals MOSPD1 and MOSPD3 as membrane contact site proteins interacting with FFAT-related FFNT motifs. Cell Rep. 2020;33:108475.
13. Nishimura AL, Mitne-Neto M, Silva HC, et al. A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. Am J Hum Genet. 2004;75:822-31.
14. Borgese N, Navone F, Nukina N, Yamanaka T. Mutant VAPB: Culprit or innocent bystander of amyotrophic lateral sclerosis? Contact (Thousand Oaks). 2021;4:25152564211022515.
15. Kors S, Costello JL, Schrader M. VAP proteins - from organelle tethers to pathogenic host interactors and their role in neuronal disease. Front Cell Dev Biol. 2022;10:895856.
16. Landers JE, Leclerc AL, Shi L, et al. New VAPB deletion variant and exclusion of VAPB mutations in familial ALS. Neurology. 2008;70:1179-85.
17. Chen HJ, Anagnostou G, Chai A, et al. Characterization of the properties of a novel mutation in VAPB in familial amyotrophic lateral sclerosis. J Biol Chem. 2010;285:40266-81.
18. van Blitterswijk M, van Es MA, Koppers M, et al. VAPB and C9orf72 mutations in 1 familial amyotrophic lateral sclerosis patient. Neurobiol Aging. 2012;33:2950.e1-4.
19. Kabashi E, El Oussini H, Bercier V, et al. Investigating the contribution of VAPB/ALS8 loss of function in amyotrophic lateral sclerosis. Hum Mol Genet. 2013;22:2350-60.
20. Sun YM, Dong Y, Wang J, Lu JH, Chen Y, Wu JJ. A novel mutation of VAPB in one Chinese familial amyotrophic lateral sclerosis pedigree and its clinical characteristics. J Neurol. 2017;264:2387-93.
21. Nishimura AL, Mitne-Neto M, Silva HC, Oliveira JR, Vainzof M, Zatz M. A novel locus for late onset amyotrophic lateral sclerosis/motor neurone disease variant at 20q13. J Med Genet. 2004;41:315-20.
22. Marques VD, Barreira AA, Davis MB, et al. Expanding the phenotypes of the Pro56Ser VAPB mutation: proximal SMA with dysautonomia. Muscle Nerve. 2006;34:731-9.
23. Kosac V, Freitas MR, Prado FM, Nascimento OJ, Bittar C. Familial adult spinal muscular atrophy associated with the VAPB gene: report of 42 cases in Brazil. Arq Neuropsiquiatr. 2013;71:788-90.
24. Di L, Chen H, Da Y, Wang S, Shen XM. Atypical familial amyotrophic lateral sclerosis with initial symptoms of pain or tremor in a Chinese family harboring VAPB-P56S mutation. J Neurol. 2016;263:263-8.
25. Guo X, Gang Q, Meng L, et al. Peripheral nerve pathology in VAPB-associated amyotrophic lateral sclerosis with dysautonomia in a Chinese family. Clin Neuropathol. 2020;39:282-7.
26. Leoni TB, Rezende TJR, Peluzzo TM, et al. Structural brain and spinal cord damage in symptomatic and pre-symptomatic VAPB-related ALS. J Neurol Sci. 2022;434:120126.
27. Lev S, Ben Halevy D, Peretti D, Dahan N. The VAP protein family: from cellular functions to motor neuron disease. Trends Cell Biol. 2008;18:282-90.
28. Dudás EF, Huynen MA, Lesk AM, Pastore A. Invisible leashes: the tethering VAPs from infectious diseases to neurodegeneration. J Biol Chem. 2021;296:100421.
29. Borgese N, Iacomino N, Colombo SF, Navone F. The link between VAPB loss of function and amyotrophic lateral sclerosis. Cells. 2021;10:1865.
30. Tsuda H, Han SM, Yang Y, et al. The amyotrophic lateral sclerosis 8 protein VAPB is cleaved, secreted, and acts as a ligand for Eph receptors. Cell. 2008;133:963-77.
31. Han SM, El Oussini H, Scekic-Zahirovic J, et al. VAPB/ALS8 MSP ligands regulate striated muscle energy metabolism critical for adult survival in caenorhabditis elegans. PLoS Genet. 2013;9:e1003738.
32. Han SM, Tsuda H, Yang Y, Vibbert J, Cottee P, Lee SJ, Winek J, Haueter C, Bellen HJ, Miller MA. Secreted VAPB/ALS8 major sperm protein domains modulate mitochondrial localization and morphology via growth cone guidance receptors. Dev Cell. 2012; 22(2):348-362.
33. Schultz J, Lee SJ, Cole T, et al. The secreted MSP domain of C. elegans VAPB homolog VPR-1 patterns the adult striated muscle mitochondrial reticulum via SMN-1. Development. 2017;144:2175-86.
34. Kamemura K, Chihara T. Multiple functions of the ER-resident VAP and its extracellular role in neural development and disease. J Biochem. 2019;165:391-400.
35. Shi J, Lua S, Tong JS, Song J. Elimination of the native structure and solubility of the hVAPB MSP domain by the Pro56Ser mutation that causes amyotrophic lateral sclerosis. Biochemistry. 2010;49:3887-97.
36. Song J. Transforming Cytosolic Proteins into “insoluble” and membrane-toxic forms triggering diseases/aging by genetic, pathological or environmental factors. Protein Pept Lett. 2017;24:294-306.
37. Kanekura K, Nishimoto I, Aiso S, Matsuoka M. Characterization of amyotrophic lateral sclerosis-linked P56S mutation of vesicle-associated membrane protein-associated protein B (VAPB/ALS8). J Biol Chem. 2006;281:30223-33.
38. Teuling E, Ahmed S, Haasdijk E, et al. Motor neuron disease-associated mutant vesicle-associated membrane protein-associated protein (VAP) B recruits wild-type VAPs into endoplasmic reticulum-derived tubular aggregates. J Neurosci. 2007;27:9801-15.
39. Gkogkas C, Middleton S, Kremer AM, et al. VAPB interacts with and modulates the activity of ATF6. Hum Mol Genet. 2008;17:1517-26.
40. Suzuki H, Kanekura K, Levine TP, et al. ALS-linked P56S-VAPB, an aggregated loss-of-function mutant of VAPB, predisposes motor neurons to ER stress-related death by inducing aggregation of co-expressed wild-type VAPB. J Neurochem. 2009;108:973-85.
41. Kim S, Leal SS, Ben Halevy D, Gomes CM, Lev S. Structural requirements for VAP-B oligomerization and their implication in amyotrophic lateral sclerosis-associated VAP-B(P56S) neurotoxicity. J Biol Chem. 2010;285:13839-49.
42. Fasana E, Fossati M, Ruggiano A, et al. A VAPB mutant linked to amyotrophic lateral sclerosis generates a novel form of organized smooth endoplasmic reticulum. FASEB J. 2010;24:1419-30.
43. Langou K, Moumen A, Pellegrino C, et al. AAV-mediated expression of wild-type and ALS-linked mutant VAPB selectively triggers death of motoneurons through a Ca2+-dependent ER-associated pathway. J Neurochem. 2010;114:795-809.
44. Moumen A, Virard I, Raoul C. Accumulation of wildtype and ALS-linked mutated VAPB impairs activity of the proteasome. PLoS One. 2011;6:e26066.
45. Papiani G, Ruggiano A, Fossati M, et al. Restructured endoplasmic reticulum generated by mutant amyotrophic lateral sclerosis-linked VAPB is cleared by the proteasome. J Cell Sci. 2012;125:3601-11.
46. Genevini P, Papiani G, Ruggiano A, Cantoni L, Navone F, Borgese N. Amyotrophic lateral sclerosis-linked mutant VAPB inclusions do not interfere with protein degradation pathways or intracellular transport in a cultured cell model. PLoS One. 2014;9:e113416.
47. Ratnaparkhi A, Lawless GM, Schweizer FE, Golshani P, Jackson GR. A drosophila model of ALS: human ALS-associated mutation in VAP33A suggests a dominant negative mechanism. PLoS One. 2008;3:e2334.
48. Forrest S, Chai A, Sanhueza M, et al. Increased levels of phosphoinositides cause neurodegeneration in a drosophila model of amyotrophic lateral sclerosis. Hum Mol Genet. 2013;22:2689-704.
49. Chaplot K, Pimpale L, Ramalingam B, Deivasigamani S, Kamat SS, Ratnaparkhi GS. SOD1 activity threshold and TOR signalling modulate VAP(P58S) aggregation via reactive oxygen species-induced proteasomal degradation in a drosophila model of amyotrophic lateral sclerosis. Dis Model Mech. 2019;12:dmm033803.
50. Thulasidharan A, Garg L, Tendulkar S, Ratnaparkhi GS. Age-dependent dynamics of neuronal VAPB(ALS) inclusions in the adult brain. Neurobiol Dis. 2024;196:106517.
51. Tudor EL, Galtrey CM, Perkinton MS, et al. Amyotrophic lateral sclerosis mutant vesicle-associated membrane protein-associated protein-B transgenic mice develop TAR-DNA-binding protein-43 pathology. Neuroscience. 2010;167:774-85.
52. Qiu L, Qiao T, Beers M, et al. Widespread aggregation of mutant VAPB associated with ALS does not cause motor neuron degeneration or modulate mutant SOD1 aggregation and toxicity in mice. Mol Neurodegener. 2013;8:1.
53. Aliaga L, Lai C, Yu J, et al. Amyotrophic lateral sclerosis-related VAPB P56S mutation differentially affects the function and survival of corticospinal and spinal motor neurons. Hum Mol Genet. 2013;22:4293-305.
54. Kuijpers M, van Dis V, Haasdijk ED, et al. Amyotrophic lateral sclerosis (ALS)-associated VAPB-P56S inclusions represent an ER quality control compartment. Acta Neuropathol Commun. 2013;1:24.
55. Tripathi P, Guo H, Dreser A, et al. Pathomechanisms of ALS8: altered autophagy and defective RNA binding protein (RBP) homeostasis due to the VAPB P56S mutation. Cell Death Dis. 2021;12:466.
56. Moustaqim-Barrette A, Lin YQ, Pradhan S, Neely GG, Bellen HJ, Tsuda H. The amyotrophic lateral sclerosis 8 protein, VAP, is required for ER protein quality control. Hum Mol Genet. 2014;23:1975-89.
57. Yamanaka T, Nishiyama R, Shimogori T, Nukina N. Proteomics-based approach identifies altered ER domain properties by ALS-linked VAPB mutation. Sci Rep. 2020;10:7610.
58. James C, Lenz C, Urlaub H, Kehlenbach RH. Sequestosome 1 Is part of the interaction network of VAPB. Int J Mol Sci. 2021;22:13271.
59. Gao XK, Sheng ZK, Lu YH, et al. VAPB-mediated ER-targeting stabilizes IRS-1 signalosomes to regulate insulin/IGF signaling. Cell Discov. 2023;9:83.
60. Mitne-Neto M, Machado-Costa M, Marchetto MC, et al. Downregulation of VAPB expression in motor neurons derived from induced pluripotent stem cells of ALS8 patients. Hum Mol Genet. 2011;20:3642-52.
61. Oliveira D, Morales-Vicente DA, Amaral MS, et al. Different gene expression profiles in iPSC-derived motor neurons from ALS8 patients with variable clinical courses suggest mitigating pathways for neurodegeneration. Hum Mol Genet. 2020;29:1465-75.
62. Larroquette F, Seto L, Gaub PL, et al. Vapb/Amyotrophic lateral sclerosis 8 knock-in mice display slowly progressive motor behavior defects accompanying ER stress and autophagic response. Hum Mol Genet. 2015;24:6515-29.
63. Murage B, Tan H, Mashimo T, Jackson M, Skehel PA. Spinal cord neurone loss and foot placement changes in a rat knock-in model of amyotrophic lateral sclerosis Type 8. Brain Commun. 2024;6:fcae184.
64. Feng G, Mellor RH, Bernstein M, et al. Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP. Neuron. 2000;28:41-51.
65. Porrero C, Rubio-Garrido P, Avendaño C, Clascá F. Mapping of fluorescent protein-expressing neurons and axon pathways in adult and developing Thy1-eYFP-H transgenic mice. Brain Res. 2010;1345:59-72.
66. Ziogas NK, Koliatsos VE. Primary Traumatic axonopathy in mice subjected to impact acceleration: a reappraisal of pathology and mechanisms with high-resolution anatomical methods. J Neurosci. 2018;38:4031-47.
67. Miedel CJ, Patton JM, Miedel AN, Miedel ES, Levenson JM. Assessment of spontaneous alternation, novel object recognition and limb clasping in transgenic mouse models of amyloid-β and tau neuropathology. J Vis Exp. 2017.
68. Yu J, Lai C, Shim H, et al. Genetic ablation of dynactin p150(Glued) in postnatal neurons causes preferential degeneration of spinal motor neurons in aged mice. Mol Neurodegener. 2018;13:10.
69. De Vos KJ, Mórotz GM, Stoica R, et al. VAPB interacts with the mitochondrial protein PTPIP51 to regulate calcium homeostasis. Hum Mol Genet. 2012;21:1299-311.
70. Chen B, Schaevitz LR, McConnell SK. Fezl regulates the differentiation and axon targeting of layer 5 subcortical projection neurons in cerebral cortex. Proc Natl Acad Sci U S A. 2005;102:17184-9.
71. Han Q, Cao C, Ding Y, et al. Plasticity of motor network and function in the absence of corticospinal projection. Exp Neurol. 2015;267:194-208.
72. Carmona LM, Thomas ED, Smith K, Tasic B, Costa RM, Nelson A. Topographical and cell type-specific connectivity of rostral and caudal forelimb corticospinal neuron populations. Cell Rep. 2024;43:113993.
73. Ueno M, Nakamura Y, Li J, et al. Corticospinal circuits from the sensory and motor cortices differentially regulate skilled movements through distinct spinal interneurons. Cell Rep. 2018;23:1286-1300.e7.
74. Wu SA, Li ZJ, Qi L. Endoplasmic reticulum (ER) protein degradation by ER-associated degradation and ER-phagy. Trends Cell Biol. 2025;35:576-91.
75. Mórotz GM, De Vos KJ, Vagnoni A, Ackerley S, Shaw CE, Miller CC. Amyotrophic lateral sclerosis-associated mutant VAPBP56S perturbs calcium homeostasis to disrupt axonal transport of mitochondria. Hum Mol Genet. 2012;21:1979-88.
76. Stoica R, De Vos KJ, Paillusson S, et al. ER-mitochondria associations are regulated by the VAPB-PTPIP51 interaction and are disrupted by ALS/FTD-associated TDP-43. Nat Commun. 2014;5:3996.
77. Martín-Guerrero SM, Markovinovic A, Mórotz GM, Salam S, Noble W, Miller CCJ. Targeting ER-mitochondria signaling as a therapeutic target for frontotemporal dementia and related amyotrophic lateral sclerosis. Front Cell Dev Biol. 2022;10:915931.
78. Obara CJ, Nixon-Abell J, Moore AS, et al. Motion of VAPB molecules reveals ER-mitochondria contact site subdomains. Nature. 2024;626:169-76.
80. Yasuda R, Hayashi Y, Hell JW. CaMKII: a central molecular organizer of synaptic plasticity, learning and memory. Nat Rev Neurosci. 2022;23:666-82.
81. Hou ST, Jiang SX, Aylsworth A, et al. CaMKII phosphorylates collapsin response mediator protein 2 and modulates axonal damage during glutamate excitotoxicity. J Neurochem. 2009;111:870-81.
82. Moutal A, White KA, Chefdeville A, et al. Dysregulation of CRMP2 post-translational modifications drive its pathological functions. Mol Neurobiol. 2019;56:6736-55.
83. Siwecka N, Rozpędek-Kamińska W, Wawrzynkiewicz A, Pytel D, Diehl JA, Majsterek I. The structure, activation and signaling of IRE1 and Its role in determining cell fate. Biomedicines. 2021;9:156.
84. Lee JK, Kim NJ. Recent Advances in the inhibition of p38 MAPK as a potential strategy for the treatment of Alzheimer’s disease. Molecules. 2017;22:1287.
85. Zhao Y, Kuca K, Wu W, et al. Hypothesis: JNK signaling is a therapeutic target of neurodegenerative diseases. Alzheimers Dement. 2022;18:152-8.
86. Yue J, López JM. Understanding MAPK signaling pathways in apoptosis. Int J Mol Sci. 2020;21:2346.
87. Tortarolo M, Veglianese P, Calvaresi N, et al. Persistent activation of p38 mitogen-activated protein kinase in a mouse model of familial amyotrophic lateral sclerosis correlates with disease progression. Mol Cell Neurosci. 2003;23:180-92.
88. Bendotti C, Atzori C, Piva R, et al. Activated p38MAPK is a novel component of the intracellular inclusions found in human amyotrophic lateral sclerosis and mutant SOD1 transgenic mice. J Neuropathol Exp Neurol. 2004;63:113-9.
89. Holasek SS, Wengenack TM, Kandimalla KK, et al. Activation of the stress-activated MAP kinase, p38, but not JNK in cortical motor neurons during early presymptomatic stages of amyotrophic lateral sclerosis in transgenic mice. Brain Res. 2005;1045:185-98.
90. Veglianese P, Lo Coco D, Bao Cutrona M, et al. Activation of the p38MAPK cascade is associated with upregulation of TNF alpha receptors in the spinal motor neurons of mouse models of familial ALS. Mol Cell Neurosci. 2006;31:218-31.
91. Dewil M, dela Cruz VF, Van Den Bosch L, Robberecht W. Inhibition of p38 mitogen activated protein kinase activation and mutant SOD1(G93A)-induced motor neuron death. Neurobiol Dis. 2007;26:332-41.
92. Sama RR, Fallini C, Gatto R, et al. ALS-linked FUS exerts a gain of toxic function involving aberrant p38 MAPK activation. Sci Rep. 2017;7:115.
93. Kuijpers M, Yu KL, Teuling E, Akhmanova A, Jaarsma D, Hoogenraad CC. The ALS8 protein VAPB interacts with the ER-Golgi recycling protein YIF1A and regulates membrane delivery into dendrites. EMBO J. 2013;32:2056-72.
94. Tran D, Chalhoub A, Schooley A, Zhang W, Ngsee JK. A mutation in VAPB that causes amyotrophic lateral sclerosis also causes a nuclear envelope defect. J Cell Sci. 2012;125:2831-6.
95. Zhao YG, Liu N, Miao G, Chen Y, Zhao H, Zhang H. The ER contact proteins VAPA/B interact with multiple autophagy proteins to modulate autophagosome biogenesis. Curr Biol. 2018;28:1234-1245.e4.
96. Karagas NE, Gupta R, Rastegari E, et al. Loss of Activity-induced mitochondrial ATP production underlies the synaptic defects in a drosophila model of ALS. J Neurosci. 2022;42:8019-37.
